{[amino(imino)methyl]amino}(dimethylamino)methaniminium salicylate | 1411413-50-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: {[amino(imino)methyl]amino}(dimethylamino)methaniminium salicylate
• 英文别名: {[Amino(imino)methyl]amino}(dimethylamino)methaniminium salicylate；[amino-(diaminomethylideneamino)methylidene]-dimethylazanium;2-carboxyphenolate
• CAS: 1411413-50-7
• 化学式: C₄H₁₁N₅*C₇H₆O₃
• 分子量: 267.288
• InChiKey: XXTQSYGJFZMOHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.15
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  149
• 氢给体数：
  5
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  二甲双胍 、 水杨酸 在 氯化钠 、 ice 作用下， 以 乙腈 为溶剂， 反应 18.13h， 以to yield 2.27 g (82%) of the title compound as a crystalline white solid的产率得到{[amino(imino)methyl]amino}(dimethylamino)methaniminium salicylate
  参考文献：
  名称：

  Metformin salts of salicylic acid and its congeners

  摘要：

  本发明涉及公式VI和公式VII化合物的制备中使用的中间体，制备这些化合物的方法，包括公式VI化合物和公式VII化合物的制药组合物，以及将公式VI化合物和公式VII化合物用作抗糖尿病、预防糖尿病、抗肥胖和心脏保护剂的用途。

  公开号：

  US08440723B2

文献信息

• Metformin Salts of Salicylic Acid and Its Congeners
  申请人：Mylari Banavara L.

  公开号：US20120289485A1

  公开（公告）日：2012-11-15

  The present invention relates to compounds, intermediates used in the preparation of such compounds, processes for the preparation of such compounds of the formula VI and formula VII and such intermediates, pharmaceutical compositions comprising such compounds of the formula VI and such compounds of the formula VII, and the uses of such compounds of the formula VI and such compounds of the formula VII as antidiabetic, pre-antidiabetic, antiobesity and cardioprotective agents.

  本发明涉及化合物、在制备这些化合物中使用的中间体、用于制备公式 VI 和公式 VII 的这些化合物以及这些中间体的过程、包含公式 VI 的这些化合物和公式 VII 的这些化合物的药物组合物，以及公式 VI 的这些化合物和公式 VII 的这些化合物作为抗糖尿病、预防糖尿病、抗肥胖和心脏保护剂的用途。
• METFORMIN SALTS OF SALICYLIC ACID AND IT CONGENERS
  申请人：Mylari Banavara L.

  公开号：US20130252926A1

  公开（公告）日：2013-09-26

  The present invention relates to compounds, intermediates used in the preparation of such compounds, processes for the preparation of such compounds of the formula VI and formula VII and such intermediates, pharmaceutical compositions comprising such compounds of the formula VI and such compounds of the formula VII, and the uses of such compounds of the formula VI and such compounds of the formula VII as antidiabetic, pre-antidiabetic, antiobesity and cardioprotective agents.

  本发明涉及公式VI和公式VII的化合物及其制备中间体，用于制备这些化合物的过程，包括公式VI的化合物和公式VII的化合物的制药组合物，以及将这些公式VI的化合物和公式VII的化合物用作抗糖尿病、预防糖尿病、抗肥胖和心脏保护剂的用途。
• Structure and Thermodynamical Properties of Metformin Salicylate
  作者：R. Pérez-Fernández、N. Fresno、P. Goya、J. Elguero、L. Menéndez-Taboada、S. García-Granda、C. Marco

  DOI：10.1021/cg400150f

  日期：2013.4.3

  The behavior under thermal conditions of the cocrystal formed by metformin and salicylic acid was studied by DSC, crystallography (single-crystal), and powder diffraction (WAXS). Metformin salicylate crystallizes in space group P2(1)/c, with the salicylate anion showing a planar structure, stabilized by strong intramolecular hydrogen bonds. The more flexible metformin cations link through the oxygen atoms of salicylate, forming a dense hydrogen-bonding network. The compound exists initially as a salt, metformin salicylate, but after melting and cooling, it is transformed into a glass form that crystallizes and melts again, showing different behaviors depending on the heating rate.
• US8440723B2
  申请人：——

  公开号：US8440723B2

  公开（公告）日：2013-05-14
• Metformin salts of salicylic acid and its congeners
  申请人：Mylari Banavara L.

  公开号：US08440723B2

  公开（公告）日：2013-05-14

  The present invention relates to compounds, intermediates used in the preparation of such compounds, processes for the preparation of such compounds of the formula VI and formula VII and such intermediates, pharmaceutical compositions comprising such compounds of the formula VI and such compounds of the formula VII, and the uses of such compounds of the formula VI and such compounds of the formula VII as antidiabetic, pre-antidiabetic, antiobesity and cardioprotective agents.

  本发明涉及公式VI和公式VII化合物的制备中使用的中间体，制备这些化合物的方法，包括公式VI化合物和公式VII化合物的制药组合物，以及将公式VI化合物和公式VII化合物用作抗糖尿病、预防糖尿病、抗肥胖和心脏保护剂的用途。